Tumor infiltrating lymphocyte (TIL) therapy entails isolating, activating, expanding, and reinfusing isolated lymphocytes from tumors, presumably representing a collection of high affinity T cells that can recognize the melanoma tumor specific peptides expressed on endogenous HLA antigens. FDA recently approved Commercial TIL (Lifileucel; Amtagvi®), for treatment of BRAF wild type/resistant, checkpoint inhibitor failure, unresectable or metastatic melanoma, based on registrational trial showing an overall response rate of 31.5% in treated patients. Following FDA approval, patient outcomes beyond the originally selected clinical trial populations remain unknown. We report initial real-world, single institutional observations and outcomes with melanoma referred for TIL therapy. Retrospective analysis of cell therapy database of outcomes in 45 patients with unresectable or metastatic melanoma referred for TIL therapy considerations are reported. The median age was 68 years (27-83),37 (82.2%) had stage IV and 38 (84.4%) had BRAF wild-type disease, and 15 (33.3%) had CNS disease. 23 patients were male (51.1%), 28 (62.2%) patients completed surgical tumor harvest, 23(51.1%) patients completed TIL infusion, and 1 patient was just starting LD chemotherapy at the time of data analysis. 3 patients died from disease progression, and one went on comfort care prior to starting lymphodepleting chemotherapy. 8 (28.5%) TIL products were out of specification. 17 referred patients did not proceed to tumor resection: 8 (47.1%) were deemed ineligible due to small tumor size (<1.5 cm), co-morbidities or nonresectable site/brain mets,3 had not definitive evidence of disease, 2 died due to rapid disease progression, 3 deferred due to autoimmune colitis from prior CPI, and pt choice (n=1). The median overall survival for all patients who successfully pursued TIL therapy was not reached with 1-year OS of 79.2% (95% CI 60.2% to 100%) compared to patients who did not pursue TIL therapy with a mOS of 10.15 months and with 1-year OS of 42% (95% CI 23.4% to 75.4%) [p 0.007] (Fig. 2). Workflow modifications were implemented as part of a quality improvement initiative after six months. Upon receipt of a TIL referral, consultation with the Cellular Therapy (CT) team was initiated, followed by an urgent referral to Surgical Oncology. A CT nurse served as the central point of contact, coordinating all subsequent encounters, including operating room scheduling, tumor collection, CT laboratory processing, and industry partner manufacturing slot allocation. Table 2 demonstrates a reduction of the average time interval between referral and CT consult (17.6 vs 10.7 days with the new workflow), and a time interval between initial referral and receiving actual TIL infusion (128 days vs 96.3 days). Our institutional real-world data show that only about half of TIL therapy referrals will proceed with the actual TIL infusions. While TIL therapy seeks to achieve the approximately 32% response rate observed in the registrational trial, real-world outcomes in an intent-to-treat population are anticipated to be inferior. Advanced melanoma affords a narrow time window from referral to completion of TIL manufacturing and infusion, necessitating efficient workflows to enable early treatment and optimize patient outcomes.